Business Wire

TX-MARY-KAY

Share
Mary Kay Inc. Expands Partnership with The Nature Conservancy to Protect Waterways Across the Globe

Last year, Mary Kay Inc ., an international leader in corporate and social responsibility, announced the company had partnered with The Nature Conservancy to protect Texas fisheries and the Gulf of Mexico . Today, Mary Kay is proud to announce they’ve expanded that partnership with The Nature Conservancy to impact waterways—and native species—the world over.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005038/en/

“All life on Earth began in and depends on our oceans,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “Water is the most valuable resource on our planet, and it’s essential that we do our part to protect it. When we began scaling our partnership with The Nature Conservancy last year, we focused on the waterways surrounding our home state of Texas. But we’re a global company, and we knew the need for support stretched far beyond the Gulf of Mexico. We’re thrilled to advance ecosystems and biodiversity conservation globally.”

Founded in 1951, The Nature Conservancy is the leading conservation organization, working around the world to protect ecologically important lands and waters for nature and people. The Conservancy’s practices are rooted in science and are driven by pragmatic solutions to the most pressing conservation threats at the largest scale.

The conservation programs are as vast and diverse as the ocean life they’re designed to protect. Beyond the Texas fisheries program, Mary Kay will also support The Nature Conservancy through the following programs:

  • Australia: In Northern Australia, Mary Kay will partner with indigenous communities to increase women’s role in conservation, including refining community-based healthy spatial development, working with government and non-government partners to scale up the adoption of conservation tools, and establishing a women’s camp at Fish River Station, a 445,000-acre property in the Northern Territory.
  • New Zealand: In New Zealand, Mary Kay and The Nature Conservancy will engage with indigenous people in sustainable aquaculture, including supporting the implementation of restorative activities in Auckland’s Hauraki Gulf to restore wild shellfish populations and launching a challenge fund to encourage greater philanthropic support for restoration of wildlife.
  • Mexico: In Mexico, Mary Kay and The Nature Conservancy will partner on the Monterrey Water Fund, which will enhance watersheds and support women in the area. These improvements include irrigation systems, a substrate study, and the diversification of plant production.
  • China: In China, Mary Kay and The Nature Conservancy will work to protect rural headwaters to secure clean drinking water for millions of people across the country. By 2021, the team will demonstrate five headwater production projects in Zhejiang, Fujian, Guangdong, and one other province.
  • General Ocean: The partnership will also mitigate plastic pollution in Indo-Pacific tuna fisheries. Together, they will work with leading plastic researchers to identify the fisheries that are the biggest contributors to ocean pollution so high-impact pilot programs and be put in place to mitigate pollution and clean up our seas.
  • Solomon Islands: In the Solomon Islands, the partnership will protect turtles through female-led ecotourism of the South Pacific Ocean. Mary Kay’s contribution will help create a viable, locally-run ecotourism venture in the Arnavon Islands that strengthens turtle conservation and provides equitable, sustainable financial returns to communities that are best positioned to protect endangered species.
  • Colombia: Through the Bogota Water Fund, the partnership will improve water security for millions of people in Colombia.
  • Canada: In Canada, Mary Kay and The Nature Conservancy will strengthen indigenous stewards by supporting current and future community leaders in traditional territories. This is an investment in a healthy future for these communities, their lands and waters for future generations.
  • Europe: In the UK and Germany, the partnership will work to protect biodiversity and marine resources as they introduce the native European oyster. In Spain, the partnership will work to create a water fund—the country currently faces some of the worst challenges in terms of water scarcity and water quality.

“We need healthy, diverse oceans for fishing, working and playing,” said Lily Verdone, Director of Freshwater and Marine at The Nature Conservancy. “But protecting oceans is about more than just protecting our planet: oceans add $1.5 trillion to the global economy each year. Mary Kay has long worked to impact change that will sustain the earth for generations to come, so they are a natural—and welcome—partner for The Nature Conservancy. We’d already seen such impactful change in Texas, and we’re thrilled to see what their contributions will help us accomplish in communities across the world.”

Mary Kay also sponsored EarthxOcean conference, a livestreaming event that brought experts, researchers and conservations together in a livestream to discuss topics such as the High Seas Initiative, coral reef restoration, ocean plastic solutions and sustainable fisheries.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, manufacture irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay FoundationSM , the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye